A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Subscribe To Our Newsletter & Stay Updated